A First-in-human Trial of GRT7041 in Healthy Participants

The purpose of this trial is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GRT7041 in healthy male and female (Women of non-childbearing potential) participants. The trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose \[SAD\]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose \[MAD\]), and the Treatment Period will be up to 14 days (for Part 2). The trial will include a Screening Visit, an in-house stay period and Follow-up (FU) Visit/End-of-Trial (EoT) Visit.

NCT Number	NCT07289776
Lead Sponsor	Grünenthal GmbH
Conditions	Treatment of Pain
Enrollment	70 participants
Start Date	2026-01-14
Primary Completion	2026-08-24 (estimated)
Study Completion	2026-08-28 (estimated)
Updated on ClinicalTrials.gov	2026-02-20